BamSEC and AlphaSense Join Forces
Learn More

PDS Biotechnology Corporation

NASDAQ: PDSB    
Share price (1/8/25): $1.57    
Market cap (1/8/25): $58.7 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 44 pages PDS Biotechnology Corporation Common Stock (Par Value $0.00033 Per Share) Amended and Restated at Market Issuance Sales Agreement
12/34/56
EX-10.1
from 8-K 1 page Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation of PDS Biotechnology Corporation
12/34/56
EX-10.3
from 10-Q 18 pages Executive Employment Agreement
12/34/56
EX-10.27
from 10-K 21 pages Executive Employment Agreement
12/34/56
EX-10.26
from 10-K 21 pages Executive Employment Agreement
12/34/56
EX-10.1
from 8-K 8 pages PDS Biotechnology Corporation 2019 Inducement Plan Amended on January 22, 2024 Section 1. General Purpose of the Plan; Definitions
12/34/56
EX-10.1
from 8-K 11 pages Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan Adopted by the Board of Directors on May 19, 2023 Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan
12/34/56
EX-10.9
from 10-K 61 pages License Agreement
12/34/56
EX-10.1
from 8-K 4 pages Share Transfer Agreement
12/34/56
EX-10.1
from 10-Q 13 pages PDS Biotechnology Corporation Warrant to Purchase Shares of Common Stock
12/34/56
EX-10.3
from 10-Q 2 pages First Amendment to Amended and Restated Preclinical/Clinical Collaboration and License Agreement
12/34/56
EX-10.2
from 10-Q 18 pages Amended and Restated Preclinical/Clinical Collaboration and License Agreement
12/34/56
EX-10.1
from 10-Q 14 pages Executive Employment Agreement
12/34/56
EX-10.1
from 8-K 8 pages PDS Biotechnology Corporation 2019 Inducement Plan Amended on May 17, 2022 Section 1. General Purpose of the Plan; Definitions
12/34/56
EX-10.25
from 10-K 17 pages Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]” Executive Employment Agreement
12/34/56
EX-10.24
from 10-K 17 pages Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]” Executive Employment Agreement
12/34/56
EX-10.23
from 10-K 17 pages Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]” Executive Employment Agreement
12/34/56
EX-10.22
from 10-K 17 pages Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]” Amended and Restated Executive Employment Agreement
12/34/56
EX-10.21
from 10-K 14 pages PDS Biotechnology Corporation Change of Control Severance Plan
12/34/56
EX-10.20
from 10-K 14 pages Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]” Option Agreement Article 1 Definitions
12/34/56